162 related articles for article (PubMed ID: 28673265)
1. A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention).
Bandak M; Jørgensen N; Juul A; Lauritsen J; Kreiberg M; Oturai PS; Helge JW; Daugaard G
BMC Cancer; 2017 Jul; 17(1):461. PubMed ID: 28673265
[TBL] [Abstract][Full Text] [Related]
2. A randomized double-blind single center study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention).
Kreiberg M; Jørgensen N; Juul A; Lauritsen J; Oturai P; Helge JW; Christensen JF; Aksglaede L; Schauer T; Wagner T; Rosenvilde J; Grunwald E; Dehlendorff C; Daugaard G; Bandak M
Clin Genitourin Cancer; 2022 Oct; 20(5):404-414. PubMed ID: 35701334
[TBL] [Abstract][Full Text] [Related]
3. Effect of Testosterone Replacement Therapy on Quality of Life and Sexual Function in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency: Results From a Randomized Double-blind Trial.
Højer EG; Kreiberg M; Dehlendorff C; Jørgensen N; Juul A; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
Clin Genitourin Cancer; 2022 Aug; 20(4):334-343. PubMed ID: 35514022
[TBL] [Abstract][Full Text] [Related]
4. Testicular cancer survivors have shorter anogenital distance that is not increased by 1 year of testosterone replacement therapy.
Priskorn L; Kreiberg M; Bandak M; Lauritsen J; Daugaard G; Petersen JH; Aksglaede L; Juul A; Jørgensen N
Hum Reprod; 2021 Aug; 36(9):2443-2451. PubMed ID: 34223605
[TBL] [Abstract][Full Text] [Related]
5. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Oturai PS; Mortensen J; Hojman P; Helge JW; Daugaard G
Eur J Cancer; 2017 Oct; 84():9-17. PubMed ID: 28772110
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency.
Medici C; Jørgensen N; Juul A; Albrethsen J; Kreiberg M; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
Clin Genitourin Cancer; 2024 Feb; 22(1):e106-e112.e4. PubMed ID: 37673783
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G
Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832
[TBL] [Abstract][Full Text] [Related]
8. Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial.
Jørgensen PL; Kreiberg M; Jørgensen N; Juul A; Oturai PS; Dehlendorff C; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Medici CR; Jørgensen NR; Bandak M
Acta Oncol; 2023 Jul; 62(7):689-695. PubMed ID: 37151105
[TBL] [Abstract][Full Text] [Related]
9. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction.
Skøtt JW; Lauritsen J; Kreiberg M; Daugaard G; Bandak M
Clin Genitourin Cancer; 2019 Feb; 17(1):e65-e71. PubMed ID: 30293923
[TBL] [Abstract][Full Text] [Related]
10. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy.
Howell SJ; Radford JA; Adams JE; Smets EM; Warburton R; Shalet SM
Clin Endocrinol (Oxf); 2001 Sep; 55(3):315-24. PubMed ID: 11589674
[TBL] [Abstract][Full Text] [Related]
11. Primary human testicular PDGFRα+ cells are multipotent and can be differentiated into cells with Leydig cell characteristics in vitro.
Eliveld J; van den Berg EA; Chikhovskaya JV; van Daalen SKM; de Winter-Korver CM; van der Veen F; Repping S; Teerds K; van Pelt AMM
Hum Reprod; 2019 Sep; 34(9):1621-1631. PubMed ID: 31398257
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β-hCG and cancer treatment.
Steggink LC; van Beek AP; Boer H; Meijer C; Lubberts S; Oosting SF; de Jong IJ; van Ginkel RJ; Lefrandt JD; Gietema JA; Nuver J
Andrology; 2019 Jul; 7(4):441-448. PubMed ID: 30609309
[TBL] [Abstract][Full Text] [Related]
14. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial.
Walsh JS; Marshall H; Smith IL; Greenfield DM; Swain J; Best E; Ashton J; Brown JM; Huddart R; Coleman RE; Snowden JA; Ross RJ
PLoS Med; 2019 Nov; 16(11):e1002960. PubMed ID: 31714912
[TBL] [Abstract][Full Text] [Related]
15. Altered bone status in unilateral testicular cancer survivors: Role of CYP2R1 and its luteinizing hormone-dependency.
Foresta C; Selice R; De Toni L; Di Mambro A; Carraro U; Plebani M; Garolla A
J Endocrinol Invest; 2013 Jun; 36(6):379-84. PubMed ID: 23047203
[TBL] [Abstract][Full Text] [Related]
16. Preorchiectomy Leydig Cell Dysfunction in Patients With Testicular Cancer.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Gundgaard Kier MG; Mortensen MS; Daugaard G
Clin Genitourin Cancer; 2017 Feb; 15(1):e37-e43. PubMed ID: 27524512
[TBL] [Abstract][Full Text] [Related]
17. Quantification of the Leydig cell compartment in testicular biopsies and association with biochemical Leydig cell dysfunction in testicular cancer survivors.
Tarsitano MG; Bandak M; Jørgensen N; Skakkebaek NE; Juul A; Lenzi A; Daugaard G; Rajpert-De Meyts E
Andrology; 2018 Sep; 6(5):748-755. PubMed ID: 29981219
[TBL] [Abstract][Full Text] [Related]
18. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors.
Gerl A; Mühlbayer D; Hansmann G; Mraz W; Hiddemann W
Cancer; 2001 Apr; 91(7):1297-303. PubMed ID: 11283930
[TBL] [Abstract][Full Text] [Related]
19. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency.
Howell SJ; Radford JA; Ryder WD; Shalet SM
J Clin Oncol; 1999 May; 17(5):1493-8. PubMed ID: 10334536
[TBL] [Abstract][Full Text] [Related]
20. Clinical presentation, management and follow-up of 83 patients with Leydig cell tumors of the testis: a prospective case-cohort study.
Pozza C; Pofi R; Tenuta M; Tarsitano MG; Sbardella E; Fattorini G; Cantisani V; Lenzi A; Isidori AM; Gianfrilli D;
Hum Reprod; 2019 Aug; 34(8):1389-1403. PubMed ID: 31532522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
